The recent statement from the International Federation for the Surgery of Obesity (IFSO) on metabolic and bariatric surgery (MBS) following pharmacotherapy-induced weight loss provides timely guidance in the era of obesity management medications (OMMs), including GLP-1 receptor agonists [
1]. By contrasting weight trajectories when MBS is performed at OMM discontinuation versus after weight regain, the statement highlights the importance of early surgical consideration and offers a practical framework for clinical decision-making. Its emphasis on avoiding delays is clinically significant, as postponing MBS may worsen outcomes, increase costs, and elevate the risk of recurrent weight gain. …